Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000224 | 1.00 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL24582713 | 1.00 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL12474768 | 0.88 | NPC1 (0.51) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL5764293 | 0.87 | DRD2 (0.53) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL4513851 | 0.87 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL4524476 | 0.87 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL4513846 | 0.87 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL7036798 | 0.86 | PTPN1 (0.52) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL7310845 | 0.85 | NPC1 (0.48) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL7038704 | 0.84 | LMNA (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081987-A2 | CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION USING NOVEL ONIUM SALT AND RESIST PATTERN FORMING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| CN-101679454-A | Antimicrobial heterocyclic compounds for treatment of bacterial infections | MICURX PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-5736518-A | Peptide compounds of (L) amino acids and ring molecules, and therapeutical applications thereof | POLIFARMA S.P.A. (IT) | 1998-04-07 | — | — | US | disclosed |
| EP-0503044-B1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF | POLIFARMA SPA (IT) | 1996-06-12 | — | — | EP | disclosed |
| US-5504071-A | HYPOTENSIVE AGENTS | POLIFARMA S.P.A. (IT) | 1996-04-02 | — | — | US | disclosed |
| EP-0244836-B1 | TRIPEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1993-08-18 | — | — | EP | disclosed |
| EP-0503044-A1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF. | POLIFARMA SPA (IT) | 1992-09-16 | — | — | EP | disclosed |
| WO-1992006108-A1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF | POLIFARMA S.P.A. (IT) | 1992-04-16 | — | — | WO | disclosed |
| US-4826814-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0244836-A2 | Tripeptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-11 | — | — | EP | disclosed |
| US-4697016-A | Intermediates for the preparation of a carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1987-09-29 | — | — | US | disclosed |
| US-4595766-A | Process for the preparation of an indoline carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | NPC1 2331/4885RAB9A 3658/4885L3MBTL1 1228/4885 |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | NPC1 1168/4885RAB9A 1349/4885L3MBTL1 3059/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | NPC1 981/4885RAB9A 1092/4885L3MBTL1 70/4885 |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | NPC1 515/4885RAB9A 1343/4885L3MBTL1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.